ArticleVaccine2005
A host-range restricted parainfluenza virus type 3 (PIV3) expressing the human metapneumovirus (hMPV) fusion protein elicits protective immunity in African green monkeys.
Article in Vaccine, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 94 citations in OpenAlex.
- Live human metapneumovirus vaccine candidates attenuated by temperature sensitivity mutations from human respiratory syncytial virus.Journal of virology · 2026Article
- A Review of Respiratory Infection Caused by the Human Metapneumovirus: Occurrence, Epidemiology, Pathogenesis, Public Health Outcomes, and Intervention Strategies.Health science reports · 2026Article
- Human metapneumovirus prevention in children: emerging roles of monoclonal antibodies and vaccines.Frontiers in immunology · 2026Review
- Intranasal bovine/human parainfluenza virus 3 vaccine candidates expressing human metapneumovirus wild-type or pre-fusion F protein elicit protective immunity against human metapneumovirus in hamsters.Journal of virology · 2025Article
- Landscape of Prophylactic Strategies Against Human Parainfluenza Virus Type 3.Reviews in medical virology · 2025Review
- Immunoinformatic design of chimeric multiepitope vaccine for the prevention of human metapneumovirus (hMPV).BMC infectious diseases · 2025Article
- Review
- Article
- Neonatal Immune Responses to Respiratory Viruses.Frontiers in immunology · 2022Review
- The role of M2-2 PDZ-binding motifs in pulmonary innate immune responses to human metapneumovirus.Journal of medical virology · 2020Article
- Prospects of and Barriers to the Development of Epitope-Based Vaccines against Human Metapneumovirus.Pathogens (Basel, Switzerland) · 2020Review
- Review
- Engineering of Live Chimeric Vaccines against Human Metapneumovirus.Pathogens (Basel, Switzerland) · 2020Review
- Human Metapneumovirus: A Largely Unrecognized Threat to Human Health.Pathogens (Basel, Switzerland) · 2020Article
- Prophylactic and therapeutic approaches for human metapneumovirus.Virusdisease · 2018Review
- Human metapneumovirus - what we know now.F1000Research · 2018Review
- Modulation of Host Immunity by the Human Metapneumovirus.Clinical microbiology reviews · 2016Review
- Human metapneumovirus in the preterm neonate: current perspectives.Research and reports in neonatology · 2016Article
- New Approaches for Immunization and Therapy against Human Metapneumovirus.Clinical and vaccine immunology : CVI · 2015Review
- Recent vaccine development for human metapneumovirus.The Journal of general virology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human metapneumovirus (hMPV) infection causes respiratory tract disease similar to that observed during human respiratory syncytial virus infection (hRSV). hMPV infections have been reported across the entire age spectrum although the most severe disease occurs in young children. No vaccines, chemotherapeutics or antibodies are presently available for preventing or treating hMPV infections. In this study, a bovine/human chimeric parainfluenza virus type 3 (b/h PIV3) expressing the human parainfluenza type 3 (hPIV3) fusion (F) and hemagglutinin-neuraminidase (HN) proteins was engineered to express hMPV fusion (F) protein from the second genome position (b/h PIV3/hMPV F2) with the goal of generating a novel hMPV vaccine. b/h PIV3/hMPV F2 was previously shown to protect hamsters from challenge with wt hMPV (Tang RS, Schickli JH, Macphail M, Fernandes F, Bicha L, Spaete J, et al. Effects of human metapneumovirus and respiratory syncytial virus antigen insertion in two 3' proximal genome positions of bovine/human parainfluenza virus type 3 on virus replication and immunogenicity. J Virol 2003;77:10819-28) and is here further evaluated for efficacy and immunogenicity in African green monkeys (AGMs). AGMs immunized intranasally and intratracheally with b/h PIV3/hMPV F2 generated hMPV- and hPIV3-specific humoral and cellular immune responses and were protected from wt hMPV infection. In a separate study, the host-range restriction of b/h PIV3/hMPV F2 replication relative to wt hPIV3 was performed in rhesus monkeys to demonstrate attenuation. These studies showed that b/h PIV3/hMPV F2 was immunogenic, protective and attenuated in non-human primates and warrants further evaluation in humans as a vaccine candidate for prevention of hMPV-associated respiratory tract diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.